Your clinic's reputation — and your DEA registration — are only as safe as the compounding pharmacy you source from. Yet most providers pick a 503A compounder based on price and a cold email. That's a mistake that can cost you your license.

Here's the checklist we use internally before recommending any 503A pharmacy to our provider network.

A 503A pharmacy must hold an active pharmacy license in the state where the patient's prescription originates — not just where the pharmacy is located. Ask for a current license certificate and verify it directly on your state board's public lookup tool. Licenses expire. Verify the date.

Sterile compounding under 503A requires compliance with USP <797> (sterile preparations) and USP <800> (hazardous drugs). Ask the pharmacy for their most recent third-party compliance audit or state inspection report. If they can't produce one, that's a red flag.

A COA is a third-party lab report confirming potency, sterility, and endotoxin levels for a specific lot of compounded product. Any legitimate 503A pharmacy provides COAs on request — and should include them automatically with every shipment. If they hesitate, walk away.

Under 503A, every compounded product must be dispensed pursuant to a valid patient-specific prescription from a licensed prescriber. If a pharmacy is offering to ship product without a prescription, or is offering "office-use" quantities without a valid prescription basis, they are operating outside 503A law. This exposes your clinic to serious liability.

Not every compound can be made under 503A. The FDA maintains a list of bulk drug substances that may be used in 503A compounding. Semaglutide and tirzepatide have had complex status histories — confirm the current status of any GLP-1 compound before ordering. Your pharmacy should be able to cite the regulatory basis for every product they sell.

BUD dates for sterile compounded products are governed by USP <797>. Ask the pharmacy how they assign BUD dates and whether they have extended BUD data backed by stability testing. Longer BUD dates require documented stability studies — not just a policy decision. Understand what you're receiving.

GLP-1 compounds require temperature-controlled shipping. Ask specifically: What carrier do they use? What packaging? What is the maximum transit time they allow? Do they include temperature monitors in shipments? A pharmacy that ships GLP-1s in standard packaging without temperature monitoring is cutting corners that affect product integrity.

Ask directly: "Have you had any back-order situations in the last 12 months?" A reliable 503A partner should be able to answer this honestly. Chronic back-orders signal capacity problems or supply chain instability. Your patients can't wait.

Every licensed pharmacy has a Pharmacist-in-Charge. You should be able to speak with a licensed pharmacist about any clinical question — formulation, stability, drug interactions. If the only contact is a sales rep, that's a problem.

Ask for a certificate of insurance showing professional liability (errors and omissions) coverage. A pharmacy that can't produce this is either uninsured or underinsured — and if something goes wrong with a compounded product, your clinic may be the only party with coverage.

Choosing a 503A compounder is a compliance decision, not just a procurement decision. The pharmacy you source from becomes part of your clinical workflow — and their failures become your liability exposure.

Run this checklist before you place your first order. If a pharmacy can't pass all 10 points, keep looking.

MedClinic Partners pre-vets every pharmacy in our network against these standards before they ever reach a provider. Our NPI-verified portal gives you access to compliant 503A supply — with COAs on every shipment, overnight cold-chain delivery, and a licensed pharmacist available for clinical questions.

Apply for portal access in under 60 seconds.